ASCO Voices from China | Professor Xinan Sheng and Professor Cuijian Zhang: First-Line Approval of Toripalimab for Metastatic Urothelial Carcinoma Marks a New Era for China-Developed Therapy and Reshapes the Treatment Landscape

 ASCO Voices from China | Professor Xinan Sheng and Professor Cuijian Zhang: First-Line Approval of Toripalimab for Metastatic Urothelial Carcinoma Marks a New Era for China-Developed Therapy and Reshapes the Treatment Landscape

For many years, platinum-based chemotherapy has remained the standard first-line treatment for urothelial carcinoma, yet outcomes have remained suboptimal. As targeted therapies and immunotherapy continue to advance rapidly, there is growing demand for more effective precision treatment strategies.
ASCO Voices from China | Professor Xuesong Li and Professor Qi Tang: Disitamab Vedotin Plus Radiotherapy Achieves a 95% 1-Year DFS Rate, Offering an Innovative Adjuvant Strategy for UTUC in China

ASCO Voices from China | Professor Xuesong Li and Professor Qi Tang: Disitamab Vedotin Plus Radiotherapy Achieves a 95% 1-Year DFS Rate, Offering an Innovative Adjuvant Strategy for UTUC in China

Upper tract urothelial carcinoma (UTUC) accounts for a substantially higher proportion of urothelial carcinoma cases in China than in Western populations. Although radical nephroureterectomy remains the standard treatment for UTUC, many patients become ineligible for cisplatin-based chemotherapy after surgery because of impaired renal function and other comorbidities. Furthermore, subgroup analyses from three major adjuvant immunotherapy trials have failed to demonstrate a significant disease-free survival (DFS) benefit in patients with UTUC, underscoring the urgent need for novel therapeutic strategies.
Professor Zhisong He and Professor Xin Yao: New Approval of Toripalimab for Urothelial Carcinoma, Chinese Clinical Evidence Powers CSCO Guidelines and Reshapes the National Treatment Landscape

Professor Zhisong He and Professor Xin Yao: New Approval of Toripalimab for Urothelial Carcinoma, Chinese Clinical Evidence Powers CSCO Guidelines and Reshapes the National Treatment Landscape

For nearly four decades, platinum-based chemotherapy has remained the standard first-line treatment for urothelial carcinoma (UC). However, its limitations—including modest survival outcomes and significant treatment-related toxicity—have persisted as major clinical challenges.
COMy 2026 | Professor Nizar Bahlis: A Comprehensive Framework for Understanding and Overcoming Bispecific Antibody Resistance in Multiple Myeloma

COMy 2026 | Professor Nizar Bahlis: A Comprehensive Framework for Understanding and Overcoming Bispecific Antibody Resistance in Multiple Myeloma

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential global meetings in the field of multiple myeloma (MM), the congress brought together leading investigators to discuss the latest advances in translational research, innovative therapies, and patient care.
COMy 2026 | Professor Philippe Moreau: Thirty-Five Years of Progress—Tracing the Evolution of Frontline Therapy for Transplant-Eligible Multiple Myeloma

COMy 2026 | Professor Philippe Moreau: Thirty-Five Years of Progress—Tracing the Evolution of Frontline Therapy for Transplant-Eligible Multiple Myeloma

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential meetings in the field of multiple myeloma (MM), the congress brought together leading experts to discuss the latest advances in research, innovative therapies, and patient care.
COMy 2026 | Professor Salomon Manier: Survival Breakthroughs and a New Era of Personalized Treatment for Transplant-Ineligible Multiple Myeloma

COMy 2026 | Professor Salomon Manier: Survival Breakthroughs and a New Era of Personalized Treatment for Transplant-Ineligible Multiple Myeloma

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential international meetings in the field of multiple myeloma (MM), the congress brought together leading experts from around the world to discuss the latest advances in research, novel therapies, and patient care.
COMy 2026 | Professor Shaji Kumar: An Early Look at the Landmark Changes in the New Multiple Myeloma Response Criteria

COMy 2026 | Professor Shaji Kumar: An Early Look at the Landmark Changes in the New Multiple Myeloma Response Criteria

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential global meetings in the field of multiple myeloma (MM), the congress brought together leading experts to discuss the latest advances in translational research, novel therapeutics, and patient care.
COMy 2026 | Professor Steven P. Treon: The Precision Era of Waldenström Macroglobulinemia—Overcoming Resistance and Exploring New Therapeutic Targets

COMy 2026 | Professor Steven P. Treon: The Precision Era of Waldenström Macroglobulinemia—Overcoming Resistance and Exploring New Therapeutic Targets

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential international meetings in the field of multiple myeloma and related plasma cell disorders, the congress brought together leading experts worldwide to discuss the latest advances in translational research, novel therapeutics, and patient care.
COMy 2026 | Honoring the Architects of Progress: Major Awards Spotlight the Past, Present, and Future of Multiple Myeloma Research

COMy 2026 | Honoring the Architects of Progress: Major Awards Spotlight the Past, Present, and Future of Multiple Myeloma Research

From May 14–17, 2026, the 12th International Congress on Controversies in Multiple Myeloma (COMy 2026) was successfully held in Paris, France. Recognized as one of the most influential academic meetings in the field of multiple myeloma (MM), COMy has long been distinguished by its focused format, in-depth scientific discussions, and emphasis on unresolved clinical questions.